NCT04643678

Anakinra in the Management of COVID-19 Infection

Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Hamad Medical Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Anakinra - an interleukin (IL)-1 receptor antagonist - had showed survival benefits in patients with macrophage activation syndrome (MAS) and sepsis and was investigated for the use in COVID-19 infection with promising outcomes.

Conditions

• Covid19
• Pneumonia
• Cytokine Release Syndrome
• Corona Virus Infection
• Viral Infection

Interventions

Type	Name	Description
DRUG	Anakinra	Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
OTHER	Standard of Care	Patients will receive the Standard of Care therapy as per the local treatment protocol

Timeline

• Start date: 2020-10-30
• Primary completion: 2021-03-01
• Completion: 2021-04-30
• First posted: 2020-11-25
• Last updated: 2022-08-16

Locations

1 site across 1 country: Qatar